Dapsone: Modes of action, toxicity and possible strategies for increasing patient tolerance

British Journal of Dermatology

Volumn 129, Issue 5, 1993, Pages 507-513

  Coleman, M D ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DAPSONE;

ARTICLE; DERMATITIS HERPETIFORMIS; ERYTHROCYTE; HEMOLYSIS; HUMAN; METHEMOGLOBINEMIA; PRIORITY JOURNAL; SKIN INFECTION;

EID: 0027366832     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1993.tb00476.x     Document Type: Article

References (75)

1. 1 Bruce‐Chwatt LJ. Essential Malariology London: Heinemann, 1982 ; 181–2.
2. 2 Lee BL, Medina I, Benowitz NL et al. Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med 1989 ; 110: 606–11.
3. 3 Berlow BA, Liebhaber MI, Dyer Z, Spiegel TM. The effect of dapsone in steroid‐dependent asthma. J Allergy Clin Immunol 1991 ; 87: 710–15.
4. 4 Person JR, Rogers RS. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977 ; 113: 610–15.
5. 5 Martin J, Roenigk HH Jr. Lynch W, Tingwald FR. Relapsing polychondritis treated with dapsone. Arch Dermatol 1976 ; 112: 1272–4.
6. 6 Thompson DM, Main RA, Swanson‐Beck J, Albert‐Recht F. Studies on a patient with leucocytoclastic vasculitis. ‘pyoderma gangrenosum’ and paraproteinaemia. Br J Dermatol: 1973 ; 88: 117–25.
7. 7 Grindulis KA, McConkey B. Rheumatoid arthritis: the effects of treatment with dapsone on haemoglobin. J Rheumatol 1984 ; 11: 776–8.
8. 8 Lang PG Jr. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1979 ; 1: 479–92.
9. 9 Zone JJ, Dermatitis herpetiformis. Curr Probl Dermatol 1991 ; 3: 4–42.
10. 10 Harrison J, Araiso T, Palcic M, Dunford H. Compound I of myeloperoxidase. Biochem Biophys Res Commun 1980 ; 94: 34–40.
11. 11 Kettle AJ, Winterbourn CC. Mechanism of inhibition of myeloperoxidase by anti‐inflammatory drugs. Biochem Pharmacol 1991 ; 41: 1485–92.
12. 12 Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989 ; 320: 365–76.
13. 13 van Zyl JM, Basson K, Kriegler A, van der Walt BJ. Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. Biochem Pharmacol 1991 ; 42: 599–608.
14. 14 Springer TA. Adhesion receptors of the immune system. Nature 1990 ; 346: 425–34.
15. 15 Booth SA, Moody CE, Dahl MV et al. Dapsone suppresses integrin‐mediated neutrophil adherence function. J Invest Dermatol 1992 ; 98: 135–40.
16. 16 Woosley RL, Drayer DE, Reidenberg MM et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978 ; 298: 1157–9.
17. 17 Israili ZH, Cucinell SA, Vaught J et al. Studies of the metabolism of DDS in man and experimental animals. Formation of N‐hydroxy metabolites. J Pharmacol Exp Ther 1973 ; 187: 138–51.
18. 18 Grossman SJ, Jollow DJ. Role of dapsone hydroxylamine in dapsone‐induced haemolytic anaemia. J Pharmacol Exp Ther 1988 ; 244: 118–25.
19. 19 Zuidema J, Hilbers‐Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clinical Pharmacokinet 1986 ; 11: 299–315.
20. 20 Gelber R, Peters JH, Gordon GR et al. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther 1971 ; 12: 225–38.
21. 21 Coleman MD, Scott AK, Breckenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N‐hydroxylation in man. Br J Clin Pharmacol 1990 ; 30: 761–7.
22. 22 Fleming CM, Branch RA, Wilkinson GR, Guengerich FP. Human liver microsomal N‐hydroxylation of dapsone by cytochrome p450IIIA4. Mol Pharmacol 1992 ; 41: 975–80.
23. 23 May DG, Porter JA, Uetrecht JP et al. The contribution of N‐hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 1990 ; 48: 619–27.
24. 24 Swain AF, Ahmad RA, Rogers HJ et al. Pharmacokinetic observations on dapsone in dermatitis herpetiformis. Br J Dermatol 1983 ; 108: 91–8.
25. 25 Cucinell SA, Israili ZH. Dayton PG. Microsomal N‐oxidation of dapsone as a cause of methaemoglobin formation in human red cells. Am J Trop Med Hyg 1972 ; 21: 322–31.
26. 26 Degowin RL, Eppes RB, Powell RD, Carson PE. The haemolytic effects of diphenylsulphone (DDS) in normal subjects and in those with glucose‐6‐phosphate dehydrogenase deficiency. Bull WHO 1966 ; 35: 165–79.
27. 27 Manfredi G, de Panfilis G, Zampetti M, Allegra F. Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G‐6‐PD activity in correlation with dapsone dosage. Br J Dermatol 1979 ; 100: 427–32.
28. 28 Kiese M, Reinwein D, Waller HD. Kinetik der Hämiglobinbildung. IV Mitteilung. Die Hämiglobinbildung durch Phenylhydroxylamin und Nitrosobenzol in roten Zellen in vitro. Naunyn Schmiedebergs Archiv Exp Path Pharmacol 1950 ; 210: 393–8.
29. 29 Kramer PA, Glader BE, Li TK. Mechanism of methaemoglobin formation by diphenylsulphones. Biochem Pharmacol 1972 ; 21: 1265–74.
30. 30 Coleman MD, Jacobus DP. Reduction of dapsone hydroxylamin in the human erythrocyte in vitro. Biochem Pharmacol 1993 ; 45: 1027–33.
31. 31 Coleman MD, Rhodes LE, Scott AK et al. The use of cimetidine to reduce dapsone‐dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol 1992 ; 34: 244–9.
32. 32 Kuma F. Properties of haemoglobin reductase and kinetic study of methaemoglobin reduction. J Biol Chem 1981 ; 256: 5518–23.
33. 33 Sass MD, Caruso CJ, Axelrod DR. Mechanism of the TPNH‐linked reduction of methaemoglobin by methylene blue. Clin Chim Acta 1969 ; 24: 77–85.
34. 34 Banzato CE, Magna LA. In vitro effect of dapsone on NADH‐methaemoglobin reductase. Int J Lepr Other Mycobact Dis 1991 ; 59: 486–7.
35. 35 Katz SI. Dapsone. In: Dermatology and General Medicine ( Fitzpatrick TB et al. eds). 3rd edn. New York: McGraw‐Hill. 1987 ; 2570–4.
36. 36 Ganer A, Knobel B, Fryd CH, Rachmilewilz EA. Dapsone‐induced methaemoglobinaemia and haemolysis in the presence of familial hemoglobinopathy Hasharon and familial methaemoglobin reductase deliciency. Isr J Med Sc 1981 ; 17: 703–4.
37. 37 Gallant JE. Hoehn‐Saric E, Smith MD. Respiratory insufficiency from dapsone‐induced methaemoglobinaemia. AIDS 1991 ; 5: 1392–3.
38. 38 Grossman SJ, Simson J, Jollow DJ. Dapsone‐induced hemolytic anemia: effect of N‐hydroxy dapsone on the sulfhydryl status and membrane proteins of rat erythrocytes. Toxicol Appl Pharmacol 1992 ; 117: 208–17.
39. 39 Kay MM. Aging of cell membrane molecules leads to appearance of aging antigen and removal of senescent cells. Gerontology 1985 ; 31: 215–35.
40. 40 Haas M, Harrison JH Jr. Stimulation of K‐CI cotransport in rat red cells by a hemolytic anemia‐producing metabolite of dapsone. Am J Physiol 1989 ; 256: C265–72.
41. 41 Graham WR Jr. Adverse effects of dapsone. Int Dermato 1975 ; 14: 494–500.
42. 42 Pengally CDR. Dapsone‐induced haemolysis. Br Med J 1963 ; 2: 662–4.
43. 43 Scott GL. Rasbridge MR. The in vitro action of dapsone and its derivatives on normal and G‐6‐PD‐deficient red cells. Br J Haematol 1973 ; 24: 307–17.
44. 44 Phillips‐Howard PA. West LJ. Serious adverse drug reactions to pyrimethamine‐sulphadoxine, pyrimethamine‐dapsone and to amodiaquine in Britain. J R Soc Med 1990 ; 83: 82–5.
45. 45 Hornsten P, Keisu M, Wilholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden. 1972 through 1988. Arch Dermatol 1990 ; 126: 919–22.
46. 46 Ognibene AJ. Agranulocytosis due to dapsone. Ann Intern Med 1970 ; 72: 521–4.
47. 47 Friman G, Nyström‐Rosander C, Jonsell G et al. Agranulocytosis associated with malaria prophylaxis with maloprim. Br Med J 1983 ; 286: 1244–5.
48. 48 Uetrecht JP. The role of leukocyte‐generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992 ; 24: 299–366.
49. 49 Weetman RM, Boxer LA, Brown MP et al. In vitro inhibition of granulopoiesis by 4‐amino‐4′‐hydroxylaminodiphenyl sulphone. Br J Haematol 1980 ; 45: 361–70.
50. 50 Coleman MD. Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 1989 ; 28: 389–95.
51. 51 Uetrecht JP, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988 ; 245: 274–9.
52. 52 Tingle MD, Coleman MD, Park BK. Investigation of the role of metabolism in dapsone‐induced methaemoglobinaemia using a two‐compartment in vitro test system. Br J Clin Pharmacol 1990 ; 30: 829–38.
53. 53 Tingle MD, Blee MAB. Coleman MD, Park BK. The use of a novel three‐compartment system to investigate cell selective drug toxicity in vitro. Br J Clin Pharmacol 1992 ; 33: 216P–217P.
54. 54 Bainton DF, Ullyot J, Farquhar MG. The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. J Exp Med 1971 ; 134: 907–34.
55. 55 Schnier GG, Laethem CL, Koop DR. Identification and induction of cytochromes P450,450IIEl and P450IAl in rabbit bone marrow. J Pharmacol Exp Ther 1989 ; 251: 790–6.
56. 56 Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1988 ; 36: 581–90.
57. 57 Spielberg SP, Boxer LA, Corash LM, Schulman JD. Improved erythrocyte survival with high‐dose vitamin E in chronic hemolyzing G6PD and glutathione synthetase deficiencies. Ann Intern Med 1979 ; 90: 53–4.
58. 58 Johnson GJ, Vatassery GT, Finkel B, Allen DW. High‐dose vitamin E does not decrease the rate of chronic hemolysis in glucose‐6‐phosphate dehydrogenase deficiency. N Engl J Med 1983 ; 308: 1014–17.
59. 59 Kelly JW, Scott J, Sandland M et al. Vitamin E and dapsone‐induced hemolysis. Arch Dermatol 1984 ; 120: 1582–4.
60. 60 Prussick R, Ali MAM, Rosenthal D, Guyatt G. The protective effect of vitamin E on the haemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992 ; 128: 210–13.
61. 61 Gordon‐Smith EC. Drug‐induced oxidative haemolysis. Clin Hematol 1986 ; 9: 557–86.
62. 62 Stratton LP, Rudolph AS, Knoll WK Jr et al. The reduction of methemoglobin levels by antioxidants. Hemoglobin 1988 ; 12: 353–68.
63. 63 Mimnaugh EG, Gram TE. Trush MA. Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterisation and effects of reactive oxygen scavengers. J Pharmacol Exp Ther 1983 ; 226: 806–16.
64. 64 Woodruff CW, Ascorbic acid. In: Nutrition ( Beaton GII, McHenry EW. eds). Vol. 2. New York: Academic Press. 1964 ; 289.
65. 65 Amery WK. De Coster R, Caers I. Ketoconazole in prostatic carcinoma. Dev Res 1986 ; 8: 299–308.
66. 66 First MR, Schroeder TJ. Alexander JW et al. Cyclosporin dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991 ; 51: 365–70.
67. 67 Frey FJ. Concomitant cyclosporin and ketoconazole. Lancet 1990 ; 335: 109–10.
68. 68 DeFelipe R, Johnson DG, Galgiani JN. Gynaecomastia with ketoconazole. Antimicrob Agents Chemother 1981 ; 19: 1073–4.
69. 69 Lewis JH, Zimmerman HJ. Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Gastroenterology 1984 ; 86: 503–13.
70. 70 Coleman MD, Winn MJ, Breckenridge AM, Park BK. Inhibition of dapsone‐induced methaemoglobinaemia in the rat. Biochem Phar-macol 1990 ; 39: 802–5.
71. 71 Coleman MD, Tingle MD, Park BK. Inhibition of dapsone‐induced methaemoglobinaemia by cimetidine in the rat during chronic dapsone administration. J Pharm Pharmacol 1991 ; 43: 186–90.
72. 72 Coleman MD. Hoaksey PE, Breckenridge AM. Park BK. Inhibition of dapsone‐induced methaemoglobinaemia in the rat isolated perfused liver. J Pharm Pharmacol 1990 ; 42: 302–7.
73. 73 Tingle MD, Coleman MD, Park BK. The effect of pre‐incubation with cimetidine on the N‐hydroxylation of dapsone by human liver microsomes, Br J Clin Pharmacol 1991 ; 32: 120–3.
74. 74 Rhodes LE, Coleman MD, Tingle MD et al. Cimetidine reduces dapsone‐induced haematological toxicity in dermatitis herpetiformis. Br J Dermatol 1992 ; 127: 426–7 (Abstr).
75. 75 Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 1987 ; 12: 321–66.